In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or perhaps the individuals are not able to tolerate the study drugs. Ubiquitin-relevant proteins that regulate the stability of key Tremendous enhancer-mediated proteins https://abbv-744-and-other-brd4-i79023.blog-eye.com/32155456/the-2-minute-rule-for-abbv-744-and-other-brd4-inhibitors-comparison